Current status of immunotherapy in metastatic colorectal cancer
P Wrobel, S Ahmed - International journal of colorectal disease, 2019 - Springer
Background Immunotherapy focuses on selectively enhancing the host's immune response
against malignant disease. It has been investigated as an important treatment modality …
against malignant disease. It has been investigated as an important treatment modality …
[HTML][HTML] The confounders of cancer immunotherapy: roles of lifestyle, metabolic disorders and sociological factors
RP Deshpande, S Sharma, K Watabe - Cancers, 2020 - mdpi.com
Simple Summary The human immune system is robustly equipped to keep unnatural cell
growth in check in the body to suppress cancer progression. However, the cells and …
growth in check in the body to suppress cancer progression. However, the cells and …
Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: a multicenter international cohort …
Importance Geriatric (aged≥ 80 years) patients are historically underrepresented in cancer
clinical trials. Little is known about the efficacy of immune checkpoint inhibitors (ICIs) in …
clinical trials. Little is known about the efficacy of immune checkpoint inhibitors (ICIs) in …
[HTML][HTML] Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer
LA Emens, S Adams, A Cimino-Mathews… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Breast cancer has historically been a disease for which immunotherapy was largely
unavailable. Recently, the use of immune checkpoint inhibitors (ICIs) in combination with …
unavailable. Recently, the use of immune checkpoint inhibitors (ICIs) in combination with …
[HTML][HTML] Immunotherapy in older adults with cancer
CJ Presley, F Gomes, CE Burd… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
Cancer is a disease of older adults. The median age at cancer diagnosis is 66 years and
median age at cancer-related death is 72 years. 1 Older adults represent one of the fastest …
median age at cancer-related death is 72 years. 1 Older adults represent one of the fastest …
[HTML][HTML] Efficacy and adverse events of immunotherapy with checkpoint inhibitors in older patients with cancer
Y van Holstein, E Kapiteijn, E Bastiaannet… - Drugs & Aging, 2019 - Springer
The number of older patients with cancer is increasing as a result of the ageing of Western
societies. Immune checkpoint inhibitors have improved cancer treatment and are associated …
societies. Immune checkpoint inhibitors have improved cancer treatment and are associated …
Research Agenda of the Oncology Nursing Society: 2019-2022.
PROBLEM STATEMENT: To define the Oncology Nursing Society Research Agenda for
2019-2022. DESIGN: Multimethod, consensus-building approach by members of the …
2019-2022. DESIGN: Multimethod, consensus-building approach by members of the …
[HTML][HTML] Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting
P Corbaux, D Maillet, A Boespflug… - European Journal of …, 2019 - Elsevier
Background Age-related immune dysfunction might impair the efficacy of immune
checkpoint inhibitors (ICIs) in older patients. We aimed to evaluate the impact of age on …
checkpoint inhibitors (ICIs) in older patients. We aimed to evaluate the impact of age on …
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
M Vithayathil, A D'Alessio, CAM Fulgenzi… - Liver …, 2022 - Wiley Online Library
Abstract Background and Aims Combination atezolizumab/bevacizumab is the gold
standard for first‐line treatment of unresectable hepatocellular carcinoma (HCC). Our study …
standard for first‐line treatment of unresectable hepatocellular carcinoma (HCC). Our study …
[HTML][HTML] A real-world study on the effectiveness and safety of pembrolizumab plus chemotherapy for nonsquamous NSCLC
D Fujimoto, S Miura, K Yoshimura, K Wakuda… - JTO Clinical and …, 2022 - Elsevier
Introduction The real-world effectiveness of combination treatment with cytotoxic
chemotherapy and programmed cell death protein-1 or programmed death-ligand 1 inhibitor …
chemotherapy and programmed cell death protein-1 or programmed death-ligand 1 inhibitor …